Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 19, 2015, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $145.00 to $4,138,406.10.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Buckley Stephen Jr., who is Director at Enanta Pharmaceuticals, bought 1,000 shares at $34.00 on Feb. 19, 2015. Following this transaction, the Director owned 2,000 shares meaning that the stake was boosted by 100% with the 1,000-share transaction.

The shares most recently traded at $34.24, up $0.24, or 0.71% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,400
  • 4-Week # shares sold: 4,500
  • 12-Week # shares bought: 1,400
  • 12-Week # shares sold: 40,500
  • 24-Week # shares bought: 1,400
  • 24-Week # shares sold: 69,500

The average volume for Enanta Pharmaceuticals has been 430,200 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $636.8 million and is part of the health care sector and drugs industry. Shares are down 33.82% year-to-date as of the close of trading on Thursday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 8.0. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Tanger Factory Outlet Centers (SKT) - FREE Research Report

Summerell Virginia R, who is Senior VP, Treasurer at Tanger Factory Outlet Centers, sold 16,026 shares at $36.81 on Feb. 19, 2015. Following this transaction, the Senior VP, Treasurer owned 33,031 shares meaning that the stake was reduced by 32.67% with the 16,026-share transaction.

The shares most recently traded at $36.13, down $0.68, or 1.9% since the insider transaction. Historical insider transactions for Tanger Factory Outlet Centers go as follows:

  • 4-Week # shares sold: 25,333
  • 12-Week # shares sold: 50,666
  • 24-Week # shares sold: 52,916

The average volume for Tanger Factory Outlet Centers has been 712,500 shares per day over the past 30 days. Tanger Factory Outlet Centers has a market cap of $3.5 billion and is part of the financial sector and real estate industry. Shares are down 2.22% year-to-date as of the close of trading on Thursday.

Tanger Factory Outlet Centers, Inc. is a real estate investment trust. The firm invests in the real estate markets in United States. It focuses on developing, acquiring, owning, operating, and managing outlet shopping centers. Tanger Factory Outlet Centers, Inc. The stock currently has a dividend yield of 2.6%. The company has a P/E ratio of 47.9. Currently, there are no analysts who rate Tanger Factory Outlet Centers a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKT - FREE

TheStreet Quant Ratings rates Tanger Factory Outlet Centers as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and feeble growth in the company's earnings per share. Get the full Tanger Factory Outlet Centers Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NuVasive (NUVA) - FREE Research Report

Hannon Jason, who is EVP, General Counsel & Sec. at NuVasive, sold 13,178 shares at $46.99 on Feb. 19, 2015. Following this transaction, the EVP, General Counsel & Sec. owned 51,086 shares meaning that the stake was reduced by 20.51% with the 13,178-share transaction.

The shares most recently traded at $47.21, up $0.22, or 0.46% since the insider transaction. Historical insider transactions for NuVasive go as follows:

  • 4-Week # shares sold: 7,539
  • 12-Week # shares sold: 13,185
  • 24-Week # shares sold: 18,185

The average volume for NuVasive has been 352,900 shares per day over the past 30 days. NuVasive has a market cap of $2.2 billion and is part of the health care sector and health services industry. Shares are up 1.19% year-to-date as of the close of trading on Thursday.

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for the spine. Its products focus on applications for spine fusion surgery. Currently, there are 10 analysts who rate NuVasive a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUVA - FREE

TheStreet Quant Ratings rates NuVasive as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full NuVasive Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null